Sector
PharmaceuticalsOpen
₹139.95Prev. Close
₹142.58Turnover(Lac.)
₹476.03Day's High
₹141.6Day's Low
₹138.5752 Week's High
₹25852 Week's Low
₹109.3Book Value
₹-4.91Face Value
₹1Mkt Cap (₹ Cr.)
4,564.72P/E
0EPS
0Divi. Yield
08 Jul 2024
12:00 AM
AGM
Announcement Date: 08 Jul, 2024
31 Jan 2025
12:00 AM
Board Meeting
Agenda : Audited Result
At the operating level, the EBITDA loss amounted to ₹102.9 Crore, a worsening from a loss of ₹91.4 Crore in the previous fiscal quarter.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 32.45 | 32.45 | 261.45 | 26.21 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 92.4 | 480.32 | -230.22 | -194.46 |
Net Worth | 124.85 | 512.77 | 31.23 | -168.25 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 252.95 | 76.81 | 78.25 | 181.02 |
yoy growth (%) | 229.3 | -1.84 | -56.76 | 12.24 |
Raw materials | -18.17 | -23.92 | -26.8 | -25.16 |
As % of sales | 7.18 | 31.14 | 34.25 | 13.89 |
Employee costs | -91.58 | -93.08 | -100.92 | -84.3 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -151.13 | -312.4 | -245.97 | -119.03 |
Depreciation | -10.92 | -9.48 | -8.18 | -8.23 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 59.11 | -68.31 | -89.36 | 46.78 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 229.3 | -1.84 | -56.76 | 12.24 |
Op profit growth | -56.46 | 27.78 | 97.72 | 94.16 |
EBIT growth | -54.64 | 25.98 | 109.73 | 72.79 |
Net profit growth | -51.62 | 58.58 | 65.49 | 70.07 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 |
|---|---|---|
Gross Sales | 75.55 | 238.78 |
Excise Duty | 0 | 0 |
Net Sales | 75.55 | 238.78 |
Other Operating Income | 0 | 0 |
Other Income | 29.47 | 10.88 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.8 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,025.5 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,480 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,141.2 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,408.2 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non Executive Director
T Rajamannar
Non Executive Director
Sudhir V Valia
Independent Director
Bhavna Doshi
Independent Director
Ferzaan Engineer
Independent Director
Robert Spiegel
Chairman (Non-Executive)
Dilip S Shanghvi
Company Sec. & Compli. Officer
Kajal Damania.
Non Executive Director
Vidhi Shanghvi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Sun Pharma Advanced Research Company Ltd
Summary
Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems. The Company works on innovation and new product development for global markets. They undertake projects in research and technology for new chemical entities (NCEs) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Limited was incorporated on March 1, 2006 as an innovative and development company. They commenced operations on March 22, 2006. As per Scheme of Arrangement, all assets and liabilities of the Innovative Research & Development business including Novel Drug Delivery System (NDDS) division of Sun Pharmaceuticals Industries Research & Development undertaking was transferred and vested into the Company with effect from February 28, 2007. The Scheme of Demerger became effective on March 28, 2007. On Scheme being effective, the Company ceased to be subsidiary of Sun Pharmaceutical Industries Ltd., and the demerged Company.During the year 2009-10, the Department of Scientific and Industrial Research (DSIR), Government of India sanctioned a 15 year unsecured soft loan under their Drug and Pharmaceutical Research Programme for a project of the Company.During 2011, the Company announced USFDA approval for DOCEFREZ (docetaxel) for Injection. During 2014, the Company announced Govt. of India approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN).On 1 December
Read More
What is the Sun Pharma Advanced Research Company Ltd share price today?
The Sun Pharma Advanced Research Company Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹140.66 today.
What is the Market Cap of Sun Pharma Advanced Research Company Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharma Advanced Research Company Ltd is ₹4564.72 Cr. as of 09 May ‘25
What is the PE and PB ratio of Sun Pharma Advanced Research Company Ltd?
The PE and PB ratios of Sun Pharma Advanced Research Company Ltd is 0 and 36.96 as of 09 May ‘25
What is the 52 Week High and Low of Sun Pharma Advanced Research Company Ltd?
The 52-week high/low is the highest and lowest price at which a Sun Pharma Advanced Research Company Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sun Pharma Advanced Research Company Ltd is ₹109.3 and ₹258 as of 09 May ‘25
What is the CAGR of Sun Pharma Advanced Research Company Ltd?
Sun Pharma Advanced Research Company Ltd's CAGR for 5 Years at 1.20%, 3 Years at -15.16%, 1 Year at -35.28%, 6 Month at -31.27%, 3 Month at -8.72% and 1 Month at -0.35%.
What is the shareholding pattern of Sun Pharma Advanced Research Company Ltd?
The shareholding pattern of Sun Pharma Advanced Research Company Ltd is as follows:
Promoters - 65.67 %
Institutions - 2.58 %
Public - 31.75 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
